iFabric (IFA) AI Stock Analysis

• Market Cap: C$36.66M
• Dividend Yield: N/A
• Average Volume (3M): 11.74K
• Price to Earnings (P/E): 39.7
• Beta (1Y): 0.52
• Revenue Growth: 18.44%
• EPS Growth: N/A
• Country: CA
• Employees: 36
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Apparel - Manufacturers
• EPS (TTM): >-0.01
• Shares Outstanding: 30,299,467
• 10 Day Avg. Volume: 8,423
• 30 Day Avg. Volume: 11,743
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: C$1.50 ▲(8.70% Upside)

iFabric's strong financial performance, characterized by robust revenue growth and improved profitability, is the most significant factor driving the score. Technical analysis indicates positive momentum, though valuation concerns due to a high P/E ratio slightly temper the overall outlook.

iFabric Business Overview & Revenue Model

Company Description

iFabric Corp. designs and distributes women's intimate apparel and accessories in Canada, the United States, the United Kingdom, Southeast Asia, and internationally. The company's Intimate Apparel division engages in the design, purchase, and distribution of intimate apparel, which includes a range of specialty bras, including reversible bra, patented bandeaux bra, and patented breast lift products. Its Intelligent Fabrics division engages in development, testing, and distribution of specialty textiles and chemicals for textiles, such as Protx2, an anti-microbial and anti-viral formulations; Enguard, an insect repellant technology; Dreamskin, a skin polymer; UVtx, an ultraviolet light blocker; FreshTx, an odor absorbing technology; RepelTX, a durable water repellant; Omega+, a joint and muscle recovery; TempTx, a thermal regulator; Apollo, a body odor neutralizer; DryTx, a moisture-wicking technology; BioTX, a metal free anti-stink solution; RepelTX Eco Plus, a fluorine-free durable water repellant; IMPRINT, a logo exposing moisture-wicker; and DriForce, a fabric interior moisture wicker. iFabric Corp. was founded in 1985 and is headquartered in Markham, Canada.

How the Company Makes Money

iFabric generates revenue through several key streams. Primarily, it earns money by selling advanced textile products to manufacturers and brands in the apparel industry. These products include performance fabrics treated with proprietary technologies that enhance their usability and longevity. Additionally, iFabric has established partnerships with various companies to co-develop specialized fabrics, which can lead to licensing agreements and royalties. The company also engages in direct sales of its own branded apparel, further diversifying its income. Revenue is bolstered by ongoing research and development efforts that keep its product offerings at the cutting edge of textile technology, enabling it to maintain competitive advantages in the market.

iFabric Financial Statement Overview

Summary

iFabric demonstrates strong financial health with robust revenue growth and improved profitability. The balance sheet reflects low leverage and strong equity financing, enhancing financial stability. Cash flow management has improved, yet there is scope for enhancing cash conversion rates. Overall, iFabric is on a positive trajectory with opportunities to strengthen cash flow dynamics.

Income Statement

The company shows strong revenue growth with a 20.3% increase from the previous year. Gross profit margin stands at 41.2%, indicating efficient cost management. The net profit margin improved significantly, moving from a negative to 6.0%, showcasing enhanced profitability. EBIT and EBITDA margins are also positive, reflecting operational efficiency.

Balance Sheet

The debt-to-equity ratio is low at 0.081, indicating prudent financial leverage. Return on Equity (ROE) is solid at 7.1%, showing effective use of equity. The equity ratio is strong at 78.4%, suggesting financial stability with a high proportion of assets financed by equity.

Cash Flow

The free cash flow growth rate improved significantly, turning positive after a previous decline, signaling better cash management. The operating cash flow to net income ratio is low at 0.18, suggesting potential cash flow volatility. The free cash flow to net income ratio is 0.13, indicating room for improvement in converting net income into cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.33M	22.72M	19.74M	19.76M	11.52M
Gross Profit	11.27M	8.84M	7.03M	7.76M	4.30M
EBITDA	2.11M	-2.21M	-27.09K	3.21M	-551.96K
Net Income	1.63M	-1.69M	-452.46K	2.37M	-624.71K
Balance Sheet
Total Assets	29.49M	25.91M	27.37M	27.63M	17.51M
Cash, Cash Equivalents and Short-Term Investments	2.06M	1.57M	944.73K	8.90M	1.16M
Total Debt	1.88M	2.03M	1.24M	1.27M	1.32M
Total Liabilities	6.35M	5.21M	4.60M	5.35M	8.17M
Stockholders Equity	23.13M	20.69M	22.75M	22.27M	9.34M
Cash Flow
Free Cash Flow	208.92K	644.99K	-8.45M	-2.48M	-1.24M
Operating Cash Flow	301.78K	833.77K	-8.21M	-2.22M	-1.06M
Investing Cash Flow	-52.86K	-138.38K	-242.76K	-253.40K	-178.02K
Financing Cash Flow	-214.74K	-14.42K	41.93K	10.46M	205.15K

iFabric Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IFA, the sentiment is Neutral. The current price of 1.38 is above the 20-day moving average (MA) of 1.28, above the 50-day MA of 1.17, and above the 200-day MA of 1.06, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:IFA.

iFabric Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GIL	―	$12.26B	19.21	31.12%	1.51%	6.64%	27.37%
IFA	―	C$36.66M	39.67	4.36%	―	18.44%	―
GOOS	―	C$1.90B	40.17	11.35%	―	2.45%	-17.73%
Sector *	―	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
MENE	―	C$61.06M	―	-1.67%	―	22.39%	90.55%
UNI	―	C$24.15M	-9.06	-16.28%	―	-3.10%	67.01%

iFabric Corporate Events

iFabric and Doctor’s Choice Collaborate on Advanced Medical Apparel

iFabric Corp’s subsidiary, IFTNA, has entered a licensing agreement with Mercury Athletics LLC to design, manufacture, and market scrubs and medical apparel under the Doctor’s Choice brand. This collaboration aims to integrate IFTNA’s textile technologies, including PROTX2®, to enhance infection-prevention and comfort in healthcare apparel, potentially strengthening iFabric’s position in the healthcare sector.

The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.

iFabric Renews Partnership with TUMI to Enhance Travel Products with Antimicrobial Technology

iFabric Corp. has announced the renewal of its license agreement with TUMI, Inc., allowing the continued integration of its PROTX2® antimicrobial solutions in select TUMI products for another five years. This partnership highlights the commitment of both companies to deliver performance, durability, and protection in travel essentials, with PROTX2 being featured in various TUMI collections, enhancing their product offerings with eco-friendly antimicrobial solutions.

The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.

iFabric Expands PROTX2 Technology to UK and EU with Marks & Spencer Partnership

iFabric Corp. has announced the expansion of its PROTX2 technology into the UK and EU markets, with Marks & Spencer adopting this technology for its Autograph collections. This strategic move marks iFabric’s shift beyond its North American focus, highlighting growing global demand for performance-enhanced fabrics and reinforcing its presence in new regional markets.

The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.

iFabric’s Antimicrobial Scrubs Prove Effective in Infection Control

iFabric Corp. has announced the publication of a clinical trial demonstrating the effectiveness of their PROTX2® and ecoPEL™ treated scrubs in reducing bacterial contamination in healthcare environments. The study, published in the Journal of Hospital Infection, highlights significant reductions in bacterial loads on scrubs, positioning iFabric’s technologies as a leading solution in infection prevention. This breakthrough offers substantial market opportunities for iFabric, as it addresses a critical need in healthcare-associated infection control, potentially reducing infection rates, readmissions, and hospital costs while extending protection beyond hospital settings.

The most recent analyst rating on (TSE:IFA) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on iFabric stock, see the TSE:IFA Stock Forecast page.

iFabric Corp Reports Stable Q2 & H1 2025 Results Amid Market Challenges

iFabric Corp reported its financial results for Q2 and H1 2025, showing stable revenues despite challenges such as U.S. tariffs and exchange losses. The company experienced a slight decrease in overall revenues due to brand advertising contributions and a weakening U.S. dollar, but it remains optimistic about future growth, with record-level deposits for future deliveries. The Intimate Apparel Division saw a 10% revenue increase, while the Intelligent Fabrics Division faced a 7% decline. iFabric is poised for expansion in the U.S. market, supported by strategic supplier and customer negotiations.